BSE - Delayed Quote INR

GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)

Compare
2,445.70 +34.55 (+1.43%)
At close: November 29 at 3:28 PM GMT+5:30
Loading Chart for GLAXO.BO
DELL
  • Previous Close 2,411.15
  • Open 2,430.10
  • Bid 2,437.85 x --
  • Ask 2,454.95 x --
  • Day's Range 2,395.00 - 2,455.00
  • 52 Week Range 1,664.75 - 3,087.95
  • Volume 1,351
  • Avg. Volume 3,526
  • Market Cap (intraday) 414.316B
  • Beta (5Y Monthly) 0.19
  • PE Ratio (TTM) 61.36
  • EPS (TTM) 39.86
  • Earnings Date Feb 10, 2025 - Feb 14, 2025
  • Forward Dividend & Yield 32.00 (1.31%)
  • Ex-Dividend Date Nov 7, 2024
  • 1y Target Est 2,914.50

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

india-pharma.gsk.com

3,211

Full Time Employees

March 31

Fiscal Year Ends

Recent News: GLAXO.BO

View More

Performance Overview: GLAXO.BO

Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GLAXO.BO
31.11%
S&P BSE SENSEX
10.47%

1-Year Return

GLAXO.BO
50.75%
S&P BSE SENSEX
20.60%

3-Year Return

GLAXO.BO
58.51%
S&P BSE SENSEX
39.74%

5-Year Return

GLAXO.BO
66.64%
S&P BSE SENSEX
94.02%

Compare To: GLAXO.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GLAXO.BO

View More

Valuation Measures

Annual
As of 11/29/2024
  • Market Cap

    414.32B

  • Enterprise Value

    392.56B

  • Trailing P/E

    61.37

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.68

  • Price/Book (mrq)

    24.77

  • Enterprise Value/Revenue

    11.06

  • Enterprise Value/EBITDA

    39.28

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.96%

  • Return on Assets (ttm)

    17.09%

  • Return on Equity (ttm)

    42.03%

  • Revenue (ttm)

    35.6B

  • Net Income Avi to Common (ttm)

    6.75B

  • Diluted EPS (ttm)

    39.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.11B

  • Total Debt/Equity (mrq)

    0.88%

  • Levered Free Cash Flow (ttm)

    9.92B

Research Analysis: GLAXO.BO

View More

Company Insights: GLAXO.BO

Research Reports: GLAXO.BO

View More

People Also Watch